Rubicon Research Ltd Board Approves AGM Date, Dividend Record Date, and Merger Scheme
Rubicon Research Ltd will hold its 27th AGM on August 26, 2026. The record date for the final dividend of ₹1.50 per share for FY26 is August 7, 2026. The Board also approved the merger scheme of its wholly owned subsidiary, Kia Health Tech Private Limited, with the company.
The approval of the merger scheme and the dividend announcement are significant corporate actions that can impact the company's structure and shareholder returns, warranting a medium impact.
The announcement details routine corporate actions like the AGM date, record date for dividend, and an approved merger scheme for a wholly owned subsidiary. While these are important, they do not immediately suggest a significant positive or negative shift in the company's immediate financial performance or outlook.
Rubicon Research Limited announced the outcome of its Board Meeting held on July 20, 2026. The Board approved the date for the 27th Annual General Meeting (AGM) to be held on Wednesday, August 26, 2026, through Video Conferencing / Other Audio Visual Means. The 'Record date' for determining eligible members for the final dividend payment for the financial year 2025-26 has been fixed as Friday, August 7, 2026.
This dividend is based on the Board's recommendation on May 29, 2026, of ₹1.50 per equity share (face value ₹1/- each fully paid-up) for the financial year ended March 31, 2026. Subject to member approval and tax deduction, the dividend will be paid within 30 days of approval, to members and beneficial owners recorded as of the close of business hours on Friday, August 7, 2026.
Furthermore, the Board approved the Scheme of Merger for Kia Health Tech Private Limited, a wholly owned subsidiary, with Rubicon Research Limited, under Section 233 of the Companies Act, 2013. The Appointed Date for the merger is April 1, 2026. As Kia Health Tech is a wholly owned subsidiary, no new shares will be issued, and no consideration will be payable, thus not affecting the shareholding pattern or voting rights. The scheme is subject to necessary approvals.
The Board Meeting commenced at 4:30 PM (IST) and concluded at 5:00 PM (IST).
What to do with a filing like this
Rubicon Research Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rubicon Research Limited. Read the original for the full detail.